General
Anonymous Unlinked Surveys
Sexually Transmitted Disease Clinics
Drug Treatment Centers
Adolescent Medicine Clinics
Job Corps Entrants
Applicants for Military Service
Blood Donors
General
Brookmeyer R. Reconstruction and future trends of the AIDS
epidemic in the United States.
Science 1991;253:37-42.
CDC.
HIV/AIDS Surveillance Report 1999, U.S. HIV and AIDS cases reported through
June 2000, Midyear edition;12(No. 1):1-42.
Accessed May 16, 2001.
CDC.
HIV/AIDS Surveillance Report 1999, U.S. HIV and AIDS cases reported through
December 1999, Year-end edition;11(No. 2):1-44.
Accessed May 16, 2001.
CDC. National HIV Prevalence Surveys: 1997 Summary.
Atlanta: CDC; 1998:1-25. Accessed May 16, 2001.
CDC.
Interpretation and use of the Western Blot assay for serodiagnosis of human
immunodeficiency virus type 1 infections. MMWR 1989;38(No.
S-7):1-7.
CDC. National HIV Serosurveillance Summary: Results through 1992.
Atlanta: CDC; 1994:1-51. Accessed May 16, 2001.
CDC.
National HIV Serosurveillance Summary:
Update–1993.
Atlanta: CDC; 1995:1-9. Accessed May 16, 2001. CDC.
CDC
Guidelines for National Human Immunodeficiency Virus Case Surveillance,
Including Monitoring for Human Immunodeficiency Virus Infection and Acquired
Immunodeficiency Syndrome. MMWR 1999;48(RR-13):1-31.
Dondero TJ, Gill ON. Large-scale HIV serologic surveys: what
has been learned? AIDS 1991;5(suppl 2):S63-9.
Dondero T, Pappaioanou M, Curran JW. Monitoring the levels and
trends of HIV infection: the Public Health Service’s HIV Surveillance
Program.
Public Health Rep 1988;103:213-20.
Fleming PL, Wortley PM, Karon JM, DeCock KM. Tracking the HIV
epidemic: current issues, future challenges.
Am J Public Health 2000;90:1037-41.
Janssen RS, Satten GA, Stramer SL, et al. New testing strategy
to detect early HIV-1 infection for use in incidence estimates and for
clinical and prevention purposes [published correction appears in
JAMA 1999;281:1893]. JAMA 1998;280:422-48.
Karon JM, Rosenberg PS, McQuillan G, Khare M, Gwinn M,
Petersen LR. Prevalence of HIV infection in the United States, 1984 to 1992.
JAMA 1996;276:126-31.
National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research.
Belmont Report: Ethical Principles and Guidelines for the Protection of
Human Subjects of Research. Washington, DC: Government Printing Office;
1988. Publication GPO 887-890.
Pappaioanou M, Dondero TJ, Petersen LR, Onorato IM, Sanchez
CD, Curran JW. The family of HIV seroprevalence surveys: objectives,
methods, and uses of sentinel surveillance for HIV in the United States.
Public Health Rep 1990;105:113-9.
Valdiserri RO, Janssen RS, Buehler JW, Fleming PL. The context
of HIV/AIDS surveillance.
J Acquir Immune Defic Syndr 2000;25:S97-S104.
Back to top
Anonymous Unlinked Surveys
Bayer R. The ethics of blinded HIV surveillance testing.
Am J Public Health 1993;83:496-7.
CDC. Protocol 2319: Anonymous Unlinked Surveys for HIV Incidence and Prevalence. Atlanta: CDC; 1999:1-78.
Back to top
Sexually Transmitted Disease Clinics
McCray E, Onorato IM. Sentinel surveillance of human
immunodeficiency virus infection in sexually transmitted disease clinics in
the United States.
J Sex Transm Dis 1992;19:235-41.
Onorato IM, McCray E, Pappaioanou M, et al. HIV seroprevalence
surveys in sexually transmitted disease clinics.
Public Health Rep 1990:105:119-24.
Valleroy LA, MacKellar DA, Karon JM, et al. HIV prevalence and
associated risks in young men who have sex with men.
JAMA 2000;284:198-204.
Weinstock HS, Sweeney S, Satten GA, Gwinn M. HIV seroincidence
and risk factors among patients repeatedly tested for HIV attending sexually
transmitted disease clinics in the United States, 1991 to 1996.
J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:506-12.
Weinstock HS, Sidhu J, Gwinn M, Karon J, Petersen LR. Trends
in HIV seroprevalence among persons attending sexually transmitted disease
clinics in the United States, 1988-1992.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:514-22.
Back to top
Drug Treatment Centers
Allen DM, Onorato IM, Green TA. HIV infection in intravenous
drug users entering drug treatment, United States, 1988 to 1989.
Am J Public Health 1992;82:541-6.
Battjes RJ, Pickens RW, Brown LS. HIV infection and AIDS risk
behaviors among injecting drug users entering methadone treatment: an
update.
J Acquir Immune Defic Syndr 1995;10:90-6.
Bordelon KA, Murrill CS, Royalty JE, Miller MS, Gwinn M.
Self-reported sexual risk behaviors among injection drug users admitted to
drug treatment. In: Abstracts for the 127th Annual Meeting and Exposition,
American Public Health Association, Chicago; November 1999. [Abstract
1015].
Hoffman JP, Su SS, Pach A. Changes in network characteristics
and HIV risk behavior among injection drug users.
Drug Alcohol Depend 1997;46:41-51.
Jones TS, Allen DM, Onorato IM, Petersen LR, Dondero TJ,
Pappaioanou M. HIV seroprevalence surveys in drug treatment centers.
Public Health Rep 1990;105:125-30.
Monterroso ER, Hamburger ME, Vlahov D, et al. Prevention of
HIV infection in street-recruited injection drug users.
JAIDS 2000;25:63-70.
Murrill CS, Tun W, Miller MS, Royalty JE, Linley LA, Gwinn M.
Reduction in self-reported injection-related risk behaviors among injecting
drug users admitted to drug treatment. In: Abstracts for the 126th Annual
Meeting and Exposition, American Public Health Association, Washington, DC;
November 1998. [Abstract 2102].
Murrill CS, Prevots DR, Miller MS, Linley LA, Royalty JE,
Gwinn M. Incidence of HIV among injection drug users entering drug treatment
programs in four U.S. cities.
J Urban Health 2001;78:152-61.
Neaigus A, Friedman SR, Jose B, et al. High-risk personal
networks and syringe sharing as risk factors for HIV infection among new
drug injectors.
J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:499-509.
Prevots DR, Allen DM, Lehman JS, Green TA, Petersen LR, Gwinn
M. Trends in human immuno-deficiency virus seroprevalence among injecting
drug users entering drug treatment centers, United States, 1988-93.
Am J Epidemiol 1996,143:733-42.
Back to top
Adolescent Medicine Clinics
Lindegren ML, Hansen C, Miller K, Byers RH, Onorato IM.
Epidemiology of human immunodeficiency virus infection in adolescents,
United States.
Pediatr Infect Dis J 1994;13:525-35.
Sweeney P, Lindegren ML, Buehler JW, Onorato IM, Janssen RS.
Teenagers at risk of human immunodeficiency virus type 1 infection.
Arch Pediatr Adolesc Med 1995;149:521-8.
Wendell DA, Onorato IM, McCray E, Allen DM, Sweeney PA. Youth
at risk: sex, drugs, and human immunodeficiency virus.
Am J Dis Child 1992;146:76-81.
Back to top
Job Corps Entrants
Conway GA, Epstein MR, Hayman CR, et al. Trends in HIV
prevalence among disadvantaged youth: survey results from a national job
training program, 1988 through 1992.
JAMA 1993;269:2887-9.
St. Louis ME, Conway GA, Hayman CR, Miller C, Petersen LR,
Dondero TJ. Human immunodeficiency virus infection in disadvantaged
adolescents: findings from the US Job Corps.
JAMA 1991;266:2387-91.
Valleroy LA, MacKellar DA, Karon JM, Janssen RS, Hayman CR.
HIV infection in disadvantaged out-of-school youth: prevalence for U.S. Job
Corps entrants, 1990 through 1996.
J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:67-73.
Back to top
Applicants for Military Service
Burke DS, Brundage JF, Goldenbaum M, et al. Human
immunodeficiency virus infections in teenagers: seroprevalence among
applicants for military service.
JAMA 1990;263:2074-7.
Brundage JF, Burke DS, Gardner LI, et al. Tracking the spread
of the HIV infection epidemic among young adults in the US: results of the
first four years of screening among civilian applicants for military
service.
J Acquir Immune Defic Syndr 1990;3:1168-80.
Back to top
Blood Donors
Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in
incidence and prevalence of major transfusion-transmissible viral infections
in US blood donors, 1991 to 1996.
JAMA 2000;284:229-35.
Back to top
|